California Biopharma Shows Promising Phase 1 Data
Research Report
Artelo Biosciences Inc. (ARTL:NASDAQ) recently reported promising Phase 1 results from its CAReS trial evaluating ART27.13 for cancer-related anorexia, according to a D. Boral Capital research note. Drug Trial Shows Positive Interim Results for ALS Treatment
Biopharmaceutical company MediciNova Inc. (MNOV:NASDAQ) announced the release of a positive interim analysis of its treatment of Amyotrophic Lateral Sclerosis (ALS). Find out why one analyst says the drug has "potential" to treat the disease and maybe others.FDA Decision on Drug for Bone Marrow Due Early 2025
Research Report
The manufacturer sheds light on the amount and remittance schedule of the cash payment it must remit to its partner if the drug gets approved, noted a Leede Financial Inc. report. Is This California Biopharma Co. In the Right Place at the Right Time?
Research Report
Roth MKM analyst Dr. Jonathan Aschoff highlighted GT Biopharma Inc.'s (GTBP:NASDAQ) development of unique precision therapeutic agents using camelid-derived nanobodies. Regenerative Medicine Co. Adds Saudi Arabia Diabetes Initiative
Leading regenerative medicine company Sernova Corp. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) announces agreement to explore fighting type I diabetes in Saudi Arabia. Read why one analyst believes the company's technology is "advanced."Approval Sought in Japan for New Drug to Lower Cholesterol
Research Report
The U.S. biopharma behind the drug is "pushing for accelerated adoption and expansion into additional territories," noted an H.C. Wainwright & Co. report. AI Accelerates Breakthroughs in Cancer Drug Discovery
Rakovina Therapeutics Inc. (RKV:TSX.V) is advancing cancer drug discovery with its Deep Docking AI platform. Read more about their recent developments and future plans.Intratubal Insemination Device Shown Effective, Safe
Research Report
Pregnancy rates with this "only new innovation for infertility in decades" were "impressive" in a pivotal study in women with male factor infertility, noted an H.C. Wainwright & Co. report. Developer of Medical Instruments Attracts Research Coverage
Research Report
Both of this Buy-rated company's two business divisions are contributing to topline growth, noted a Leede Financial Inc. report. Two Firms Aim To Create Functional Cure for Type 1 Diabetes
Each company is pursuing its own treatment approach to achieve insulin independence, consisting of islet cells (donor or stem cell derived), delivered into the portal vein or housed in a Cell Pouch bio-hybrid organ that is implanted in the body. Learn more about their respective programs.Biotech Initiates Phase III Trial for Heart Disease Drug
Clinical-stage life sciences company Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) is setting up a phase III trial for its pericarditis drug, CardioRx, after pilot study sees success. Read why analysts like this biotech stock.Breakthrough Therapy Shows Promising Long-Term Results for Depression
Cybin Inc. (CYBN:NYSE American; CYBN:NEO) has announced positive results from its 12-month Phase 2 study of CYB003, a proprietary deuterated psilocin program designed for the adjunctive treatment of major depressive disorder (MDD). Find out about the FDA's designation of this treatment and why the Chief Medical Officer sees this news as "highly encouraging."Analyst Says Biotech's Data Supports Advancement Into Phase III
Research Report
Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) recently released updated Phase II data from the MAvERIC trial testing CardiolRx in recurrent pericarditis, according to a Leede Financial Inc. research note. Transformative Moves in Harm Reduction Expanding Market Reach with New Partnerships and Acquisitions
Safe Supply Streaming Co. Ltd (SPLY:CSE; SSPLF:OTCQB; QM4:FSE) recently announced significant developments within its portfolio company, Safety Strips, and a key acquisition. Learn more about how these strategic developments aim to enhance harm reduction efforts and expand market reach.Opportunity Arises for Co. With Cell Pouch
Research Report
This medical device owner could team up with a biotech firm that just prioritized its diabetes program, noted a Leede Financial Inc. report.